Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 02 06 2019
accepted: 02 08 2019
revised: 30 07 2019
pubmed: 12 8 2019
medline: 26 2 2020
entrez: 12 8 2019
Statut: ppublish

Résumé

Our aim was to investigate sebaceous differentiation in thymus tumours and to identify new actionable genomic alterations. To this end we screened 35 normal and 23 hyperplastic thymuses, 127 thymomas and 41 thymic carcinomas for the presence of sebaceous differentiation as defined by morphology and expression of adipophilin and androgen receptor (AR). One primary thymic carcinoma showed morphology of sebaceous carcinomas (keratinizing and foam cells, calcifications, giant cells), a strong expression of adipophilin and AR together with squamous markers. NGS revealed high-level amplification of fibroblast growth factor receptor 2 (FGFR2). In thymuses and thymomas, no cells with sebaceous morphology were present. Occasionally, macrophages or epithelial cells showed adipophilin-positivity, however, without co-expression of AR. Thymic sebaceous carcinoma should be considered if a thymic carcinoma shows clear or foamy features. Testing for FGFR2 amplification might be warranted when searching for actionable genomic alterations in sebaceous carcinomas in the mediastinum and in other locations.

Identifiants

pubmed: 31401665
doi: 10.1007/s00428-019-02644-3
pii: 10.1007/s00428-019-02644-3
doi:

Substances chimiques

Biomarkers, Tumor 0
FGFR2 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 2 EC 2.7.10.1

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-327

Références

Virchows Arch. 2018 May;472(5):877-880
pubmed: 29556777
Int J Surg Pathol. 2013 Oct;21(5):526-30
pubmed: 23358435
Histopathology. 2019 Sep;75(3):431-436
pubmed: 31050844
Nat Commun. 2018 May 14;9(1):1894
pubmed: 29760388
Hum Pathol. 2019 Apr;86:124-128
pubmed: 30537491
Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872
pubmed: 29936878
Hum Pathol. 1984 Apr;15(4):341-3
pubmed: 6714965
Head Neck Pathol. 2018 Mar;12(1):118-122
pubmed: 28721661
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139
Cancer. 2011 Oct 1;117(19):4396-405
pubmed: 21437890
J Pathol. 2016 Sep;240(1):84-95
pubmed: 27287813
Histopathology. 2018 Oct;73(4):585-592
pubmed: 29856905
Gynecol Oncol Rep. 2018 Aug 29;26:37-40
pubmed: 30225334
Intern Med. 2015;54(3):351-2
pubmed: 25748747
Am J Surg Pathol. 2002 Jun;26(6):795-8
pubmed: 12023586

Auteurs

Stefan Porubsky (S)

Institute of Pathology, University Medical Centre Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. Stefan.porubsky@umm.de.

Peter Jessup (P)

Department of Pathology, Royal Hobart Hospital, Hobart, Australia.

Damien Kee (D)

Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cancer and Stem Cell Division, Walter and Eliza Hall Medical Research Institute, Parkville, Victoria, Australia.

Rajiv Sharma (R)

Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Australia.

Ayame Ochi (A)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Huiling Xu (H)

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Jens J Froelich (JJ)

Department of Medical Imaging, Interventional and Neurointerventional Services, Royal Hobart Hospital, Hobart, Australia.

Louise Nott (L)

Department of Medical Oncology, Royal Hobart Hospital, Hobart, Australia.

Clare Scott (C)

Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cancer and Stem Cell Division, Walter and Eliza Hall Medical Research Institute, Parkville, Victoria, Australia.

Raef Awad (R)

Department of Radiation Oncology, Royal Hobart Hospital, Hobart, Australia.

Cristina Moldovan (C)

Department of Medical Oncology, Royal Hobart Hospital, Hobart, Australia.

Ashutosh A Hardikar (AA)

Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Australia.

Hanibal Bohnenberger (H)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Stefan Küffer (S)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Philipp Ströbel (P)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Alexander Marx (A)

Institute of Pathology, University Medical Centre Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH